Failure of treatment with cephalexin for Lyme disease.

CONTEXT Lyme disease typically presents with a skin lesion called erythema migrans (EM), which though often distinctive in appearance may be confused with cellulitis. The first-generation cephalosporin, cephalexin monohydrate, is effective for treating bacterial cellulitis but has not been recommended or studied for treating Lyme disease because of poor in vitro activity. OBJECTIVE To describe the outcome of patients with EM who were treated with cephalexin. PATIENTS AND METHODS Patients presenting with EM to the Lyme Disease Diagnostic Center in Westchester, NY (May 1992-September 1997). A 2-mm punch biopsy specimen of the leading edge of the EM lesion and/or blood was cultured for Borrelia burgdorferi. RESULTS Eleven (2.8%) of 393 study patients had been initially treated with cephalexin prior to our evaluation; 9 (82%) were originally diagnosed with cellulitis. Cephalexin was administered for 8.6 days (range, 2-21 days) prior to presentation. All 11 patients had clinical evidence of disease progression, including 8 whose rash enlarged, 2 who developed seventh-nerve palsy (1 with new EM lesions), and 1 who developed new EM lesions. Borrelia burgdorferi grew in cultures from 5 patients despite a mean of 9.8 days of treatment with cephalexin (range, 5-21 days). CONCLUSION Cephalexin should not be used to treat early Lyme disease and should be prescribed with caution during the summer months for patients believed to have cellulitis in locations where Lyme disease is endemic.

[1]  M. Finland,et al.  Cephalexin and cephaloglycin activity in vitro and absorption and urinary excretion of single oral doses in normal young adults. , 1968, Applied microbiology.

[2]  A. Steere,et al.  Treatment of the early manifestations of Lyme disease. , 1983, Annals of internal medicine.

[3]  B. Wilske,et al.  In vitro and in vivo susceptibility of Borrelia burgdorferi. , 1987, European journal of clinical microbiology.

[4]  R. C. Johnson,et al.  In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents , 1987, Antimicrobial Agents and Chemotherapy.

[5]  K. Waxman,et al.  Comparative study of cephalexin hydrochloride and cephalexin monohydrate in the treatment of skin and soft tissue infections , 1988, Antimicrobial Agents and Chemotherapy.

[6]  R. C. Johnson,et al.  In-vitro and in-vivo susceptibility of Borrelia burgdorferi to azithromycin. , 1990, The Journal of antimicrobial chemotherapy.

[7]  Antibiotic susceptibility of Borrelia burgdorferi in vitro and in animal models. , 1991, Scandinavian journal of infectious diseases. Supplementum.

[8]  D. Jobe,et al.  In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone , 1992, Antimicrobial Agents and Chemotherapy.

[9]  A. Lebech,et al.  Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. , 1992, Acta dermato-venereologica.

[10]  J. J. Schwartz,et al.  Diagnosis of early Lyme disease by polymerase chain reaction amplification and culture of skin biopsies from erythema migrans lesions , 1992, Journal of clinical microbiology.

[11]  Vesicular erythema migrans. , 1992, Archives of dermatology.

[12]  R. C. Johnson,et al.  Cultivation of Borrelia burgdorferi from erythema migrans lesions and perilesional skin , 1992, Journal of clinical microbiology.

[13]  J. Jorgensen,et al.  Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi , 1993, Antimicrobial Agents and Chemotherapy.

[14]  R. Nadelman,et al.  Failure to isolate Borrelia burgdorferi after antimicrobial therapy in culture-documented Lyme borreliosis associated with erythema migrans: report of a prospective study. , 1993, The American journal of medicine.

[15]  R. Nadelman,et al.  Erythema migrans and early Lyme disease. , 1995, The American journal of medicine.

[16]  H. Feder,et al.  Misdiagnosis of erythema migrans. , 1995, The American journal of medicine.

[17]  Y. Yanagihara,et al.  In vitro and In vivo Antibiotic Susceptibility of Lyme Disease Borrelia Isolated from the Ixodid Tick in Japan , 1995, The Journal of dermatology.

[18]  B. Luft,et al.  Azithromycin Compared with Amoxicillin in the Treatment of Erythema Migrans: A Double-Blind, Randomized, Controlled Trial , 1996, Annals of Internal Medicine.

[19]  R. Nadelman,et al.  Lyme borreliosis , 1998, The Lancet.